Receptors of vessel endothelial growth factor 1 and 2 type at significant interleukin-16 levels in the serum of the blood of patients with new bone formations
- Authors: Babkina I.V1, Gershtein E.S1, Bondarev A.V2, Soloviev Y.N1, Boulitcheva I.V3, Chernomaz I.S1, Shchupak Y.M2, Aliev M.D1, Kushlinskii N.E1
-
Affiliations:
- A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia
- Moscow Oncological Hospital № 62
- N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
- Issue: Vol 22, No 6 (2019)
- Pages: 36-43
- Section: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112648
- DOI: https://doi.org/10.29296/25877313-2019-06-06
- ID: 112648
Cite item
Abstract
Keywords
Full Text
About the authors
I. V Babkina
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia
Email: docbabkina@rambler.ru
Dr.Sc. (Med.), Professor, Department of Clinical Biochemistry and Laboratory Diagnostics Moscow
E. S Gershtein
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of RussiaDr.Sc. (Biol.), Professor Moscow
A. V Bondarev
Moscow Oncological Hospital № 62Oncologist Moscow
Yu. N Soloviev
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of RussiaDr.Sc. (Med.), Professor, Academician of RAS Moscow
I. V Boulitcheva
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of RussiaDr.Sc. (Med.), Pathologist Moscow
I. S Chernomaz
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of RussiaPost-graduate Student, Department of Clinical Biochemistry and Laboratory Diagnostics Moscow
Yu. M Shchupak
Moscow Oncological Hospital № 62Oncologist, Head of Surgical Department Moscow
M. D Aliev
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of RussiaDr.Sc. (Med.), Professor, Academician of RAS Moscow
N. E Kushlinskii
A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of RussiaDr.Sc. (Med.), Professor, Correspondent Member of RAS Moscow
References
- Grignani G., Palmerini E., Dileo P., Asaftei S.D., D'Ambrosio L., Pignochino Y., Mercuri M., Picci P., Fagioli F., Casali P.G., Ferrari S., Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study // Ann. Oncol. 2012; 23(2):508-516.
- Raciborska A., Bilska K. Sorafenib in patients with progressed and refractory bone tumors // Med. Oncol. 2018; 35(10): 126.
- Glade Bender J.L., Lee A., Reid J.M., Baruchel S., Roberts T., Voss S.D., Wu B., Ahern C.H., Ingle A.M., Harris P., Weigel B.J., Blaney S.M. Phase I pharmacokinetic and pharmacodynamics study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group Phase I consortium report // J. Clin. Oncol. 2013;31(24): 3034-3043.
- Mori Y., Kinoshita S., Kanamori T., Kataoka H., Joh T., Iida S., Takemoto M., Kondo M., Kuroda J., Komatsu H. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib // Intern. Med. 2018; 57(18): 2753-2757.
- Fox E., Aplenc R., Bagatell R., Chuk M.K., Dombi E., Goodspeed W., Goodwin A., Kromplewski M., Jayaprakash N., Marotti M., Brown K.H., Wenrich B., Adamson P.C., Widemann B.C., Balis F.M. A phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors // J. Clin. Oncol. 2010; 28(35): 5174-5181.
- van Cruijsen H., Voest E.E., Punt C.J., Hoekman K., Witteveen P.O., Meijerink M.R., Puchalski T.A., Robertson J., Saunders O., Jürgensmeier JM., van Herpen C.M., Giaccone G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours // Eur. J. Cancer. 2010; 46(5):901-911.
- Dubois S.G., Shsterman S., Ingle A.M. Ahern C.H., Reid J.M., Wu B., Baruchel S., Glade-Bender J., Ivy P., Grier H.E., Adamson P.C., Blaney S.M. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study // Clin. Cancer. Res. 2011; 17:5113-5122.
- Versleijen-Jonkers Y.M., Vlenterie M., van de Luijtgaarden A.C., van der Graaf W.T. Anti-angiogenic therapy, a new player in the field of sarcoma treatment // Crit. Rev. Oncol. Hematol. 2014:91(2): 172-185.
- Sia D., Alsinet C., Newell P., Villanueva A. VEGF signaling in cancer treatment // Curr. Pharm. Des. 2014; 20(17):2834-2842.
- Yellapa A., Bitterman P., Sharma S., Guirguis A.S., Bahr J.M., Basu S., Abramowicz J.S., Barua A. Interleukin 16 expression changes in association with ovarian malignant transformation // Am. J. Obstet. Gynecol. 2014; 210(3):272.e1-10.
- Tang Y.J., Wang J.L., Xie K.G., Lan C.G. Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk // Sci. Rep. 2016; 6:34607.
- Бабкина И.В., Бондарев А.В., Щупак М.Ю., Кузнецов И.Н., Соловьев Ю.Н., Алиев М.Д., Кушлинский Н.Е. Перспективы исследования интерлейкина-16 и фактора роста эндотелия сосудов у больных опухолями костей // Саркомы костей, мягких тканей и кожи. 2015; 2:23-30